Global Osteoporosis Drugs Market Growth 2023-2029

Global Osteoporosis Drugs Market Growth 2023-2029

Osteoporosis is a disease where decreased bone strength increases the risk of a broken bone. It is the most common reason for a broken bone among the elderly. Bones that commonly break include the back bones, the bones of the forearm, and the hip. Until a broken bone occurs there are typically no symptoms. Bones may weaken to such a degree that a break may occur with minor stress or spontaneously. Chronic pain and a decreased ability to carry out normal activities may occur following a broken bone.

Osteoporosis may be due to lower than normal peak bone mass and greater than normal bone loss. Bone loss increases after menopause due to lower levels of estrogen. Osteoporosis may also occur due to a number of diseases or treatments including alcoholism, anorexia, hyperthyroidism, surgical removal of the ovaries, and kidney disease. Certain medications increase the rate of bone loss including some antiseizure medications, chemotherapy, proton pump inhibitors, selective serotonin reuptake inhibitors, and steroids. Not enough exercise and smoking are also risk factors. Osteoporosis is defined as a bone density of 2.5 standard deviations below that of a young adult. This is typically measured by dual-energy X-ray absorptiometry at the hip.

LPI (LP Information)' newest research report, the “Osteoporosis Drugs Industry Forecast” looks at past sales and reviews total world Osteoporosis Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Osteoporosis Drugs sales for 2023 through 2029. With Osteoporosis Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Osteoporosis Drugs industry.

This Insight Report provides a comprehensive analysis of the global Osteoporosis Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Osteoporosis Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Osteoporosis Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Osteoporosis Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Osteoporosis Drugs.

The global Osteoporosis Drugs market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

In Brazil, Osteoporosis Drugs key players include Eli Lilly, Novartis, Pfizer, etc. Global top three manufacturers hold a share over 35%.

In terms of product, Antiresorptive Drugs is the largest segment, with a share over 70%. And in terms of application, the largest application is Female, followed by Male.

This report presents a comprehensive overview, market shares, and growth opportunities of Osteoporosis Drugs market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

Antiresorptive Drugs

Anabolic Drugs

Segmentation by application

Female

Male

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Eli Lilly

Novartis

Pfizer

Amgen

Merck

Novo nordisk

Actavis

Roche

Key Questions Addressed in this Report

What is the 10-year outlook for the global Osteoporosis Drugs market?

What factors are driving Osteoporosis Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Osteoporosis Drugs market opportunities vary by end market size?

How does Osteoporosis Drugs break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.